Conduit Pharmaceuticals (CDT) Stock

Revenue of $12.7 million and earnings per share of $0.14 impacted by reduced project activity due to a slowdown in the PRC economy Revenue of $12.7 million and earnings per share of $0.14 impacted by reduced project activity due to a slowdown in the PRC economy

Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring. This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company's lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders.

SAN DIEGO and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) --   Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a broad spectrum of autoimmune disorders.

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties.

Conduit Pharmaceuticals (NASDAQ: CDT ) stock is up on Wednesday following a shareholder update concerning a major investor in the company. New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited holds a 14.8% stake in CDT stock.

Initial joint project in Fuzhou expected to generate an increase in revenue by more than 50% over next three years Initial joint project in Fuzhou expected to generate an increase in revenue by more than 50% over next three years

Three Phase Project Will Process 400,000 Tons/Day and Has Initial Contract Value of 1.16B RMB Three Phase Project Will Process 400,000 Tons/Day and Has Initial Contract Value of 1.16B RMB

SHENZHEN, China, May 20, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) (“CDT”), a leading provider of waste treatment systems and services throughout China, today announces that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2024. The annual report on Form 20-F, which contains CDT's audited consolidated financial statements, can be accessed through the SEC's website at www.sec.gov or CDT's website at https://www.cdthb.cn.